DJ Jackson

King's College London — United Kingdom

Medicine · Health Sciences

4h-index46citations47works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(29), Pediatric health and respiratory diseases(9), Eosinophilic Esophagitis(6), Chronic Obstructive Pulmonary Disease (COPD) Research(3), Urticaria and Related Conditions(3)

Publications47 total

M24 The prevalence of psychological symptoms in severe and difficult asthma
2025
P195 Phenotypic characteristics associated with frequent asthma exacerbations on tezepelumab
2025
S104 Blood and airway eosinophils in severe eosinophilic asthma are phenotypically and functionally distinct
2025
P18 Real-world experience of dupilumab for the treatment of severe asthma in the United Kingdom: a retrospective study
2024· 1 cited
P130 Clinical effectiveness over 2 years of benralizumab treatment in patients with severe eosinophilic asthma and concomitant nasal polyposis; analysis from the BPAP study
2023Open Access
P131 Patients with severe eosinophilic asthma achieved remission over 2 years with benralizumab: integrated analysis of the >1000-patient, multinational, real-world XALOC-1 study
2023Open Access
P11 Characteristics and long-term real-world outcomes of severe asthma patients treated with benralizumab in the United Kingdom; the BPAP study
2022· 1 cited
Rhinovirus-induced epithelial RIG-I inflammasome activation suppresses antiviral immunity and promotes inflammatory responses in virus-induced asthma exacerbations and COVID-19
2021· 5 citedOpen Access
P203 Effectiveness of anti-IL4R therapy following Suboptimal Response to anti-IL5/5R therapy in severe eosinophilic asthma
2021Open Access
S85 Clinical characteristics associated with mucus plugging in severe eosinophilic asthma and the effectiveness of benralizumab treatment
2021· 1 citedOpen Access
L8 Asthma deaths in Scotland during the first peak of COVID-19: Did reduced hospital admission result in excess asthma mortality?
2021Open Access
P105 Does asthma control change when patients transition to home administration of mepolizumab?
2021· 2 cited
S29 Longitudinal systemic corticosteroid utilisation for asthma and other diseases in the United Kingdom from 1990 to 2018: a population-based cohort analysis
2021· 8 cited
P116 Factors associated with hospital admission for patients presenting with an acute asthma exacerbation
2021
P107 The impact of anti-IL5/5R biologic therapies on specific domains of the Asthma Control Questionnaire
2021· 1 cited
S25 The impact of COVID-19 on the UK severe asthma population
2021· 1 citedOpen Access
P115 Adherence to inhaled corticosteroids (ICS) according to demographic characteristics in asthma
2021· 1 cited
P98 Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
2021
P103 The relationship between FeNO and response to anti-IL5/5R biologic therapies in severe eosinophilic asthma
2021
P100 Real word effectiveness of anti IL-5/IL-5R therapies in severe asthma with fungal sensitisation
2021· 1 cited
page 1 of 3Next →

Frequent Co-authors

Cris Roxas(22), G d’Ancona(20), J Kavanagh(19), AM Nanzer(18), Mariana Fernandes(17), Jaideep Dhariwal(17), BD Kent(15), L Thomson(12), L Green(9), Paul Pfeffer(8), Rekha Chaudhuri(7), AH Mansur(7), A Hearn(5), Liam G. Heaney(5), John Busby(5), Sebastian L. Johnston(4), Andrew Menzies‐Gow(4), AP Hearn(4), A Menzies-Gow(3), Hassan Burhan(3)